You are here

valrox

Is valrox dead?

Is valrox dead?

EP Vantage

Flag link:

FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries

FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries

Fierce Biotech

Flag link:

Go or no go? Valuable drugs set for FDA decisions

Go or no go? Valuable drugs set for FDA decisions

EP Vantage

belantamab mafodotin

Gilead Sciences

Flag link:

10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says

10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says

BioSpace

Bristol-Myers Squibb

Flag link:

BioMarin's Novel Treatment Promises to Disrupt Competitors

BioMarin's Novel Treatment Promises to Disrupt Competitors

Motley Fool

Flag link:

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

Motley Fool

priority review

Flag link:

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Forbes

Flag link:

BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

Motley Fool

Flag link:

BioMarin talks down worries on gene therapy data differences

BioMarin talks down worries on gene therapy data differences

Biopharma Dive

Flag link:

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

Fierce Biotech

valoctocogene roxaparvovec

Flag link:

How BioMarin May Revolutionize the Hemophilia Treatment Market

How BioMarin May Revolutionize the Hemophilia Treatment Market

Motley Fool

Flag link:

Two drugs in the pipeline representing unique marketing challenges

Two drugs in the pipeline representing unique marketing challenges

Medical Marketing and Media

Boehringer Ingelheim

Flag link:

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Endpoints

Flag link: